Plasma Derived Therapies Market Size, Share, Growth, and Industry Analysis, By Type (Immunoglobulin, Coagulation factors & Albumin), By Application (Hemophilia, Primary immunodeficiency disease & Idiopathic thrombocytopenic purpura), and Regional Forecast to 2033

Last Updated: 14 January 2025

PLASMA DERIVED THERAPIES MARKET OVERVIEW

The global Plasma Derived Therapies Market size was USD 43.75 billion in 2024 and is projected to touch USD 96.83 billion by 2033, exhibiting a CAGR of 9.23% during the forecast period.

The plasma-derived therapies market covers the production and sale of innovative medicines made from human plasma used to address diseases, disorders, and diseases and disorders of the immune system, bleeding disorders, and neurological diseases and disorders. These therapies employ proteins like immunoglobulins, clotting factors, and albumin to offer important treatments to the patients. The market is growing because more people are seeking these treatments, improved manufacturing techniques, and the aging population with chronic diseases. The companies in this market have been strategically aiming at diversifying the existing product range and enhancing the value of plasma derivatives.

COVID-19 IMPACT

Plasma Derived Therapies Industry Had a positive Effect Due to Pandemic Boost during COVID-19

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The growing concern regarding new treatment options during and post-COVID has helped the plasma-derived therapies market and achieved a positive growth rate. As there was a gradual shift toward immunoglobulins and clotting factor therapies in severe COVID-19 cases, the market experienced growth in production as well as innovations. In the same way, the pandemic increased attention to plasma donations and the efficiency of therapies, and thus the sector has received more attention. In general, the crisis contributed to further development and to growth in the market during this period.

LATEST TREND

"Market growth is driven by individualized treatments"

This report provides information on issues facing the plasma-derived therapies market, such as new therapies, progress in production processes, and investment in research. One example is pharma as a trend predominantly bound to the process of individualization, where therapy is aimed at the particular patient for the best results. This is following advancements in detection methods and increased knowledge on the causes of the diseases. Customized names are increasingly representing a core value within the biopharmaceutical sector, especially for organizations that seek to improve the effectiveness and quality of the treatments.

PLASMA DERIVED THERAPIES MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into Immunoglobulin, Coagulation factors & Albumin

• Immunoglobulin: Immunoglobulin therapies are used in immune deficiencies, autoimmune diseases, and in infections in which antibodies are given to the immune system to fight. Immunoglobulin products are in significant demand, as the product overcame long-term treatments such as primary immunodeficiencies. Higher annual growth rates and development of new production processes, as well as the growing number of autoimmune diseases, are key market drivers in this segment.
• Coagulation Factors: Coagulation factor replacement products are essentially essential for the treatment of bleeding disorders, including hemophilia, that affect people with missing clotting factors. Patients here referred to therapy as it assists in the management and reduction of bleeding experience, thus enhancing the patients’ quality of life. The increasing knowledge of what it is to have hemophilia and other similar diseases is the main driving force for increased use of coagulation factors.
• Albumin: Albumin is another plasma protein mainly being used in intensive care as a treatment for burns, shock, or liver diseases because it contributes to the volume status of the body and to the oncotic pressure. Such factors as liver diseases, as well as trauma cases, which are on the rise, are the main reasons behind the need for albumin therapies. Improvements in methods of extraction and purification of albumin have in recent years also broadened their therapeutic uses.

By Application

Based on Application, the global market can be categorized into Hemophilia, Primary immunodeficiency disease & Idiopathic thrombocytopenic purpura

• Hemophilia: Hemophilia is a genetic disease in which blood does not have blood that is deficient of clotting factors. Coagulation factors are used primarily for controlling and preventing bleeding factors in hemophilia patients. This segment is being spurred by high incidence and advance diagnosis of hemophilia coupled with the need for specific plasma-derived products.
• Primary Immunodeficiency Disease: Primary Immunodeficiency Diseases (PIDDs) arise when parts of the immune system are impaired, and therefore persons affected are vulnerable to conditions. Ig therapies based on plasma are employed for the treatment of immunodeficiency diseases due to a lack of specific antibodies in circulation. There are new developments in its diagnostic rates and increased awareness of immunoglobulin treatment, which are also increasing the market size for this segment.
• Idiopathic Thrombocytopenic Purpura: ITP is an autoimmune thrombocytopenic disease with easy bruising and bleeding due to thrombocytopenia, of which the etiology remains unknown. Plasma derivatives, especially immunoglobulins, are widely employed to raise platelet count and to avoid bleeding complications in ITP. These treatments are being demanded more frequently as awareness of ITP has risen and because immunoglobulin therapies have shown to be effective.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.  

Driving Factors

"Market growth is driven by rising chronic disease incidence and advancements"

an increasing incidence of chronic and other rare diseases like hemophilia, primary immunodeficiency diseases, and autoimmune disorders has also fueled the plasma-derived therapies market. These ailments call for long-term and specific remedies; the demand for the plasma-derived products, such as immunoglobulins and clotting factors, is rather steady. As these conditions increase as the global population ages, new and reliable therapies for treatment are increasingly sought after. This is because such diseases are now well understood by the public and are diagnosed early enough to warrant turning to a prosthetic limb. Therefore, market growth is likely to be persistent due to the necessity of special therapies in the market. Market Gets Boost with Technological Advancements in Plasma Collection and Processing A major segment of the bioinformatics equipment and supplies market, consisting of plasma-derived therapies, has experienced enhanced quality and efficiency due to technological advancement in plasma collection and processing and resulting plasma-derived therapies market growth.

"Technological innovations drive market growth by improving plasma-derived therapies' efficiency"

Technological innovations in plasma collection and processing have improved the efficiency and quality of plasma-derived therapies, driving the market forward. Improvements of plasma fractionation, purification, and concentration have enabled the production of therapeutic products that are more effective and safe. Such innovations have not only led to improvement in capacities but also brought down the cost of production that has made treatments affordable. Also, there are newer advances in how automation and bioengineering are satisfying the increasing need for these therapies. For this reason, these technologies remain a key driver of the expansion of the plasma-derived therapies market. North America leads the plasma-derived therapies market due to better healthcare facilities, increasing requirements for specific treatments, and growing R&D investments. 

Restraining Factor

"High manufacturing costs hinder market growth and availability of therapies"

The plasma-derived therapies market has one major limiting factor, and it is the high cost of manufacturing. Even sample collection, processing, and purification of plasma demand highly sophisticated equipment and a very high standard of quality control, therefore being costly to manufacture. Such costs are recovered from the client, making the treatment expensive to an extent of being unaffordable in poor, productive areas. Also, the constant pressure to develop new products and services and the safety requirement result in extra costs. In turn, such high production costs may obstruct the availability of therapies and, thus, affect market development in some segments.

Opportunity

Market growth opportunities arise from expansion into emerging healthcare markets

One of the pressing opportunities for the plasma-derived therapies market is the expansion into emerging markets. As the formal healthcare setup advances and awareness of plasmids increases in several developed regions such as Asia Pacific, Latin America, and the Middle East, there exists clear viability for growth in the market. Higher health care expenditure is on the rise in conjunction with elevated instances of chronic and orphan diseases demanding superior therapeutic solutions. The governments and health care systems in these regions are also concentrating on enhancing the availability of superior innovative treatment. These growth opportunities in more emergent markets then mean that both a new patient base and unestablished revenue channels exist within the plasma therapy field.

Challenge

"Limited plasma availability challenges market growth and sustainable development"

One would have to agree that a vital problem of the plasma-derived therapies market is the limited availability of donor plasma, which is required to produce those therapies. Plasma collection and its donation are restricted by law and are noncontinuous processes, thus affecting the production potential. However, plasma demand and various factors, including donor eligibility, safety issues, and geographical distribution of donors, can affect the availability of plasma. This causes supply to be affected, especially during peaks or during other unprecedented happenings across the globe. There is a need for companies to increase expenditures on plasma collection networks and availability to cope with increasing demands. Both of these challenges are essential to address to maintain the sustainable development of the market.

PLASMA DERIVED THERAPIES MARKET REGIONAL INSIGHTS

• North America

Market growth in North America is driven by advanced healthcare infrastructure

 North America dominates the plasma-derived therapies market due to advanced healthcare infrastructure, high demand for specialty treatments, and significant investment in research and development. region benefits from a well-established regulatory environment and leading plasma therapy manufacturers. United State Plasma-Derived Therapies Market benefits from emerging technologies and has a large healthcare system that ultimately helps to develop markets for plasma-derived products. The United States has a high rate of adoption of new techniques in treatment, hence a constant demand for plasma-derived products. In addition, the concentration of large market players also speaks volumes for North America’s position on the international market. The usage in the United States is due to the augmentation in health costs and in the proportion of elderly people.

• Europe

Market growth in Europe is driven by demand and R&D investment

Europe holds remarkable plasma-derived therapies market share due to its well-developed resources in the healthcare sector and stringent governmental guidelines. An increase in the frequency of the chronic and rare diseases has also led to the increase in the need for plasma-derived products such as immunoglobulins and clotting factors. Europe is also an important market for research and development because many stakeholders are investing in plasma therapies in their companies. The rising demand for enhancing the patient’s accessibility to these therapies also supports the growth of the market in the region.

•  Asia

Market growth in Asia is driven by improved healthcare and demand

The plasma-derived therapies market is experiencing a major contribution from Asia due to the improvement in healthcare systems and the growing knowledge of plasma therapies in the region. The patient pool for plasma-derived therapeutics is also expected to grow large, especially in the Asia-Pacific region, particularly China and India; the rise in demand is quite perceptible. It is also observing enhanced plasma collection networks, which would facilitate increased production rates. In addition, increased disposable income, coupled with improved quality of healthcare, will result in an increasing number of patients getting access to innovative treatments. It was identified that the key players are increasing their regional coverage via Asia by launching new cooperation and investment projects. Therefore, Asia is poised with high growth potential as a major contributor in the plasma-derived therapies market.

KEY INDUSTRY PLAYERS

"Market growth is fueled by innovation, partnerships, and global expansion"

Some of the key end users are dynamically affecting the plasma-derived therapies market growth through innovation, capacity expansion, and global availability of the therapies. In enhancing the efficiency and safety of plasma-derived products, they are the leading investors in research and development. The companies are also entering into strategic partnerships, acquisitions, and geographic expansion to increase their market hold to meet increasing global requirements for these solutions.

LIST OF TOP PLASMA DERIVED THERAPIES COMPANIES

• SA (US)
• Takeda Pharmaceutical Company Limited (Japan)
• Grifols (Spain)
• Octapharma (Switzerland)
• Pfizer (US)

KEY INDUSTRY DEVELOPMENT

October 2024:Grifols, a global leader in plasma-derived therapies, announced the acquisition of a state-of-the-art plasma fractionation facility in North America. This acquisition is aimed at increasing production capacity for life-saving plasma-derived therapies, such as immunoglobulins and clotting factor concentrates, to meet the rising demand due to the global increase in autoimmune and bleeding disorders. The new facility will also enhance Grifols' ability to produce therapies for rare and chronic diseases, expanding its product portfolio. This development is a direct response to the growing need for plasma-derived treatments as more patients worldwide are diagnosed with conditions that require ongoing treatment with these therapies. Grifols also emphasized its commitment to sustainability by incorporating eco-friendly practices in the new facility. This expansion supports the broader goal of improving global access to high-quality plasma-derived therapies while reducing production.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential Applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

This research report examines the segmentation of the market by using both quantitative and qualitative methods to provide a thorough analysis that also evaluates the influence of strategic and financial perspectives on the market. Additionally, the report's regional assessments consider the dominant supply and demand forces that impact market growth. The competitive landscape is detailed meticulously, including shares of significant market competitors. The report incorporates unconventional research techniques, methodologies and key strategies tailored for the anticipated frame of time. Overall, it offers valuable and comprehensive insights into the market dynamics professionally and understandably.